Analytical Data
-
基因名
BRLF1
- Application
-
别名
BRLF1；MCAF；MCAF1；Activating transcription factor 7-interacting Protein 1
-
种属
E.coli
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q3KSS7
-
表达区间
352-605aa
-
氨基酸序列
PRLRAPKSRRTSRPNRGQTPCPSNAEEPEQPWIAAVHQESDERPIFPHPSKPTFLPPVKRKKGLRDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGSPWANRPLPASLAPTPTGPVHEPVGSLTPAPVPKPLDPAPAVTPEASHLLEDPDEETSQAVKALREMADTVIPQKEEAAICGQMDLNHPPPRGHLDELTTTLESMTEDLNLDSPLTPELNEILDTFLNDECLLHAMHISTGLSIFDTSLF
-
分子量
34.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BRLF1 is a critical viral protein encoded by the Epstein-Barr virus (EBV), a member of the Herpesviridae family, known for its association with various malignancies such as nasopharyngeal carcinoma and lymphoproliferative disorders. As a transcriptional activator, BRLF1 plays a pivotal role in the lytic cycle of EBV, facilitating the transition from latency to lytic replication. The protein interacts with various cellular factors and contributes to the deregulation of host cell pathways, ultimately promoting viral replication and pathogenicity. Research on BRLF1 has gained momentum due to its potential as a therapeutic target; understanding its structure and function could unravel novel strategies to combat EBV-related diseases. Additionally, studies exploring BRLF1's role in immune evasion provide insights into the virus's ability to persist in the host. Recombinant BRLF1 protein has been produced to investigate these mechanisms further, enabling the characterization of its interactions with host proteins and the immune response. By elucidating the molecular dynamics of BRLF1, researchers aim to develop antiviral strategies and improve diagnostic approaches for EBV-associated illnesses.
